Skip to main content
Clinical Trials/NCT00763061
NCT00763061
Completed
Phase 4

A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research1 site in 1 country111 target enrollmentMay 2006

Overview

Phase
Phase 4
Intervention
Travoprost 0.004% Ophthalmic Solution (Travatan)
Conditions
Glaucoma
Sponsor
Alcon Research
Enrollment
111
Locations
1
Primary Endpoint
Mean Intraocular Pressure (IOP) at 9 AM
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

Detailed Description

To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

Registry
clinicaltrials.gov
Start Date
May 2006
End Date
April 2008
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • ≥18 years;
  • IOP=16-30mmHg
  • OH or OAG with visual filed abnormality:
  • ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p \<5% on the prepapillary diameter plot, one of which must have p \<1%,
  • Glaucoma Hemifield Test outside normal limits,
  • Corrected Pattern Standard Deviation with p \<5%

Exclusion Criteria

  • Previous damage of anterior chamber angle;
  • ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) \<1.0;
  • contact lens wearer;
  • severe central field loss;
  • uncontrolled cardiovascular, hepatic or renal disease;
  • any medication within past 1 month.

Arms & Interventions

Travoprost 0.004%

Travoprost 0.004%

Intervention: Travoprost 0.004% Ophthalmic Solution (Travatan)

Timolol 0.5%

Timolol 0.5%

Intervention: Timolol 0.5% Ophthalmic Solution (Timoptic)

Outcomes

Primary Outcomes

Mean Intraocular Pressure (IOP) at 9 AM

Time Frame: At Week 12 - At the 9 AM time point for the patient's worse eye.

Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

Week 12 - Mean IOP At 4 PM

Time Frame: At the 4 PM time point for the patient's worse eye.

Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.

Secondary Outcomes

  • Mean IOP Change From Baseline at 9 AM(Baseline to Week 12 - at 9 AM)
  • Mean IOP Change at 4 PM(Baseline to Week 12 - at 4 PM)

Study Sites (1)

Loading locations...

Similar Trials